PUBLISHER: Coherent Market Insights | PRODUCT CODE: 1608839
PUBLISHER: Coherent Market Insights | PRODUCT CODE: 1608839
Eye Inflammation Treatment Market, By Drug Class, By Dosage Form, By Distribution Channel, By Geography
Eye inflammation treatment market is estimated to be valued at USD 621.9 Mn in 2024 and is expected to reach USD 926.8 Mn by 2031, exhibiting a compound annual growth rate (CAGR) of 5.9% from 2024 to 2031.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2023 | Market Size in 2024: | 621.9 Mn |
| Historical Data for: | 2019 to 2023 | Forecast Period: | 2024 to 2031 |
| Forecast Period 2024 to 2031 CAGR: | 5.90% | 2031 Value Projection: | 926.8 Mn |
Eye inflammation, also known as ophthalmia, refers to the swelling and irritation of the eyes. It is usually caused by infections, allergies or other medical conditions. Rising geriatric population susceptible to age-related ocular disorders, growing prevalence of conjunctivitis cases worldwide and new product launches can boost demand for eye inflammation drugs and devices. Advancements in drug delivery methods and sustained release formulations have improved treatment effectiveness and patient compliance. High costs of newer treatment options and patent expiries of blockbuster drugs pose challenges for the market growth. Ongoing research on novel drugs and drug-device combination therapies can offer market growth opportunities.
Market Dynamics
Eye inflammation treatment market growth is driven by growing prevalence of eye inflammations like conjunctivitis and uveitis, increasing incidence of allergies and autoimmune diseases affecting eye health, and launch of newer drugs with improved efficacy. However, high costs of biologics and cell therapy can hamper the market growth. Development of combination therapies utilizing drugs and drug delivery devices, emergence of biosimilars, and expansion in emerging economies can offer growth opportunities for market players. Patent expiries of blockbuster drugs and stringent regulatory framework for approval of new ophthalmic products can hamper the market growth.
Key features of the study
This report provides in-depth analysis of the global eye inflammation treatment market, and provides market size (USD Mn) and compound annual growth rate (CAGR%) for the forecast period (2024-2031), considering 2023 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global eye inflammation treatment market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include GSK plc., Merck & Co. Inc., Alimera Sciences, Inc., AbbVie Inc., Teva Pharmaceutical Industries Ltd., Akron Pharma Inc., Intas Pharmaceuticals Ltd., Mylan N.V., Amgen Inc., Pfizer Inc., and Macleods Pharmaceuticals Ltd.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
Global eye inflammation treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global eye inflammation treatment market
Market Segmentation
- By Drug Class Insights (Revenue, USD Mn, 2019 - 2031)
- Corticosteroids
- Antibiotics
- Monoclonal Antibodies
- Antifungals
- Cycloplegic Agents
- Others
- By Dosage Form Insights (Revenue, USD Mn, 2019 - 2031)
- Eye Drops
- Tablets
- Capsules
- Others
- By Distribution Channel Insights (Revenue, USD Mn, 2019 - 2031)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Regional Insights (Revenue, USD Mn, 2019 - 2031)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players Insights
- GSK plc.
- Merck & Co. Inc.
- Alimera Sciences, Inc.
- AbbVie Inc.
- Teva Pharmaceutical Industries Ltd.
- Akron Pharma Inc.
- Intas Pharmaceuticals Ltd.
- Mylan N.V.
- Amgen Inc.
- Pfizer Inc.
- Macleods Pharmaceuticals Ltd.
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Eye Inflammation Treatment Market, By Drug Class
- Eye Inflammation Treatment Market, By Dosage Form
- Eye Inflammation Treatment Market, By Distribution Channel
- Eye Inflammation Treatment Market, By Region
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Impact Analysis
- Key Highlights
- Regulatory Scenario
- Product Launches/Approvals
- PEST Analysis
- PORTER's Analysis
- Merger and Acquisition Scenario
- Epidemiology
- Pipeline Analysis
4. Eye Inflammation Treatment Market, By Drug Class, 2019-2031, (USD Mn)
- Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
- Corticosteroids
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
- Antibiotics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
- Monoclonal Antibodies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
- Antifungals
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
- Cycloplegic Agents
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
5. Eye Inflammation Treatment Market, By Dosage Form, 2019-2031, (USD Mn)
- Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
- Eye Drops
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
- Tablets
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
- Capsules
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
6. Eye Inflammation Treatment Market, By Distribution Channel, 2019-2031, (USD Mn)
- Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
7. Eye Inflammation Treatment Market, By Region, 2019 - 2031, (USD Mn)
- Introduction
- Market Share (%) Analysis, 2024,2027 & 2031, (USD Mn)
- Market Y-o-Y Growth Analysis (%), 2020 - 2031, (USD Mn)
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, By Drug Class, 2019 - 2031, (USD Mn)
- Market Size and Forecast, By Dosage Form, 2019 - 2031, (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2019 - 2031, (USD Mn)
- Market Size and Forecast, By Country, 2019 - 2031, (USD Mn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, By Drug Class, 2019 - 2031, (USD Mn)
- Market Size and Forecast, By Dosage Form, 2019 - 2031, (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2019 - 2031, (USD Mn)
- Market Size and Forecast, By Country, 2019 - 2031, (USD Mn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, By Drug Class, 2019 - 2031, (USD Mn)
- Market Size and Forecast, By Dosage Form, 2019 - 2031, (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2019 - 2031, (USD Mn)
- Market Size and Forecast, By Country, 2019 - 2031, (USD Mn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, By Drug Class, 2019 - 2031, (USD Mn)
- Market Size and Forecast, By Dosage Form, 2019 - 2031, (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2019 - 2031, (USD Mn)
- Market Size and Forecast, By Country, 2019 - 2031, (USD Mn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, By Drug Class, 2019 - 2031, (USD Mn)
- Market Size and Forecast, By Dosage Form, 2019 - 2031, (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2019 - 2031, (USD Mn)
- Market Size and Forecast, By Country, 2019 - 2031, (USD Mn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, By Drug Class, 2019 - 2031, (USD Mn)
- Market Size and Forecast, By Dosage Form, 2019 - 2031, (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2019 - 2031, (USD Mn)
- Market Size and Forecast, By Country/Region, 2019 - 2031, (USD Mn)
- South Africa
- North Africa
- Central Africa
8. Competitive Landscape
- GSK plc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Merck & Co. Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Alimera Sciences, Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- AbbVie Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Teva Pharmaceutical Industries Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Akron Pharma Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Intas Pharmaceuticals Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Mylan N.V.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Amgen Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Pfizer Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Macleods Pharmaceuticals Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
9. Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
10. References and Research Methodology
- References
- Research Methodology
- About us
